SEUL KIM: Open Payments
NPI 1790316768 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$297 in 11 payments from 8 companies in 2025. Trend: 2023 $108 · 2024 $93 · 2025 $297
Food & beverage: $297
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 3 | $106 |
| Novartis Pharmaceuticals Corporation | 1 | $32 |
| Merck Sharp & Dohme LLC | 2 | $31 |
| AstraZeneca Pharmaceuticals LP | 1 | $30 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $29 |
| Incyte Corporation | 1 | $26 |
| SpringWorks Therapeutics, Inc. | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $19 |
Products named: TECVAYLI, KISQALI, Nubeqa, KEYTRUDA, KEYTRUDA QLEX.
Industry payments across MD — which companies pay providers there.
